Orion Corporation: Managers’ transactions – Minna Maasilta

ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MAY 2026 at 16.00 EEST Orion Corporation: Managers’ transactions – Minna Maasilta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Minna Maasilta Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 154837/4/6 ____________________________________________ Transaction date: 2026-04-30 Venue: OFF-EXCHANGE LIIKETOIMET (XOFF) Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 358 Unit price: 0 EUR Aggregated transactions (1): Volume: 358 Volume weighted average price: 0 EUR Orion Corporation Liisa Hurme President and CEO Mikko Kemppainen General Counsel Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland http://www.orionpharma.com Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.